Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kobe
Clinical trial register · Japan

Clinical Trials in Kobe, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca23 Eli Lilly and Company19 Janssen Research & Development, LLC18 Merck Sharp & Dohme LLC16 Novartis Pharmaceuticals16
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kobe

236 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
4D Molecular Therapeutics
Phase 3
514
Mito, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagoshima, Kita-Gun, Kobe
2026-09-18
Recruiting
AstraZeneca
Phase 3
950
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku
2026-09-16
Recruiting
UCB Biopharma SRL
Phase 3
100
Kobe
2026-09-16
Recruiting
AstraZeneca
Phase 3
1,330
Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe
2026-09-15
Recruiting
Takeda
Phase 3
324
Chiba, Toon-shi, Kobe, Hitachi, Tsu, Miyazaki, Bunkyo-Ku, Chuo-shi
2026-09-10
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Not yet open
Breakthrough Platform Trial for PCAS
NCT07769086Cardiac Arrest (CA), Post Cardiac Arrest Syndrome
Kagawa University
Not applicable
630
Chiba, Iizuka, Hiroshima, Kobe, Kita-gun, Kyoto, Sendai, Okayama
2026-09-01
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Kobe, Kyoto, Suita-shi, Tsuchiura-shi
2026-08-11
Recruiting
Janssen Research & Development, LLC
Phase 3
348
Kawasaki, Kobe, Kodaira-shi, Maebashi, Minatoku, Mitaka, Nagasaki, Sapporo
2026-07-23
Recruiting
Insmed Incorporated
Phase 3
344
Chiba, Narashino, Yahatanishi-ku, Kita Kyushu-shi, Sapporo, Kobe, Okayama, Minato-ku, Mitaka-shi
2026-07-21
Recruiting
AstraZeneca
Phase 3
915
Fukuoka, Hamamatsu, Hirosaki-shi, Kanazawa, Kashihara-shi, Kawasaki-shi, Kita-gun, Kobe
2026-07-16
Recruiting
AstraZeneca
Phase 3
600
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki
2026-07-08
Recruiting
AbbVie
Phase 3
531
Toyoake, Hirosaki, Fukuoka, Sapporo, Kobe, Sagamihara-shi, Sendai, Niigata
2026-07-02
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
20
Nagoya, Sapporo, Kobe, Chūō, Fukuoka, Kyoto
2026-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Kobe, Sendai
2026-06-18
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Kamogawa, Sapporo, Kobe, Shiwa-Gun, Tsu, Bunkyo Ku, Bunkyo-ku, Chūō
2026-05-27
Recruiting
UCB Biopharma SRL
Phase 3
120
Kobe
2026-05-27
Recruiting
Pemafibrate for Symptomatic ICAS RCT
NCT07562178Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia, Stroke (CVA) or TIA
DrugPemafibrate
Tokyo Women's Medical University
Not applicable
270
Toyoake, Yachiyo, Fukuyama, Hiroshima, Kobe, Tsukuba, Hizume, Kagoshima
2026-05-26
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bunkyō City, Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku
2026-05-22
Recruiting
AbbVie
Phase 3
990
Kashiwa-shi, Matsuyama, Kobe, Kawasaki-shi, Osaka, Koto-ku
2026-05-22
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki
2026-05-20
Recruiting
Novartis Pharmaceuticals
Observational
10
Kobe, Ushiku, Kanoya, Yokohama, Osaka
2026-05-13
Recruiting
Eli Lilly and Company
Phase 2
531
Chūōku, Fujiidera, Isehara, Kobe, Kumamoto, Sapporo, Shinjuku-Ku
2026-05-06
Recruiting
AstraZeneca
Phase 3
670
Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
342
Chūōku, Isehara, Kobe, Sapporo, Shinjuku-Ku
2026-04-29
Recruiting
MDT-0123 Japan Study
NCT07414745Disc Degeneration, Spinal Deformity
Medtronic Spinal and Biologics
Phase 3
140
Kobe, Isehara, Higashiosaka, Koshigaya, Hamamatsu, Adachi-Ku, Minato-Ku, Nakano-Ku
2026-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tōon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
Eisai Co., Ltd.
Phase 2
256
Nagoya, Toyoake, Kitakyushu, Sapporo, Kobe, Nishinomiya, Sendai, Naha
2026-03-31
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Kobe, Shiwa-gun Yahaba-cho, Koto-ku, Toyoma, Fukuoka, Niigata
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 3
850
Nagoya, Kobe, Nishinomiya, Sagamihara, Yokohama, Sendai, Hirakata, Sakai
2026-03-16
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Nagoya, Chiba, Kitakyushu-shi, Fukushima, Asahikawa-shi, Sapporo, Kobe, Kanazawa
2026-03-10
Active, closed
Ipsen
Phase 1
6
Kanagawa, Kobe, Kyoto, Osaka, Tokyo
2026-03-10
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Kobe, Bunkyo Ku, Chiyoda-ku
2026-03-09
Recruiting
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
NCT07605819Pancreatic Cancer, Pancreatic Neoplasms
Cosomil, Inc.
Not applicable
10,000
Nagakute, Nagoya, Hiroshima, Onomichi, Obihiro, Sapporo, Kobe, Mito
2026-02-04
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
266
Akita, Chiba, Maebashi, Sapporo, Kobe, Sagamihara-shi, Kochi, Nagano
2026-02-04
Recruiting
Sanofi
Phase 3
751
Bunkyō City, Chikushino-shi, Hachiōji, Kagoshima, Kamakura, Kashiwa, Kobe, Kōriyama
2026-01-16
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Asahikawa, Sapporo, Kobe
2026-01-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Nagoya, Kashiwa, Otashi, Sapporo, Himeji, Kobe, Shiwa-gun Yahaba-cho, Kawasaki
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Nagoya, Toyoake, Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Yokohama
2025-12-31
Recruiting
AstraZeneca
Phase 3
1,100
Akashi-shi, Chūōku, Hidaka-shi, Kashiwa, Kobe, Kōtoku, Kurume-shi, Nagoya
2025-12-29
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Nagoya, Kurume-Shi, Hiroshima, Sapporo, Fukuoka, Akashi, Kobe, Yokohama
2025-12-22
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto Gun, Yokohama
2025-12-19
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Chūōku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe
2025-12-12
Recruiting
Daiichi Sankyo
Phase 1
60
Kashiwa-shi, Kobe, Kōtoku, Sakura-shi
2025-12-03
Recruiting
Eli Lilly and Company
Phase 3
7,140
Chūōku, Hamadayama, Suginami-ku, Izumisano, Kobe, Kofu, Kumamoto, Shinjuku-ku, Takarazuka
2025-12-01
Recruiting
Amgen
Phase 3
750
Nagoya, Matsuyama, Fukuoka, Kobe, Kanazawa, Kita-gun, Sagamihara-shi, Osaka
2025-11-28
Active, closed
Novartis Pharmaceuticals
Phase 1
6
Nagoya, Kobe, Bunkyo Ku, Koto Ku
2025-11-26
Active, closed
Bayer
Phase 2
60
Nagoya, Kobe, Chuo-Ku, Osaka
2025-11-19
Active, closed
Pfizer
Phase 2
42
Kobe, Kawasaki, Okayama
2025-11-10
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Sapporo, Kobe, Osaka
2025-10-20
Recruiting
Eli Lilly and Company
Phase 3
1,100
Chūōku, Fukuoka, Karatsu, Kobe, Nagasaki, Nakano, Nishi, Shibuya City
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Chūōku, Fukuoka, Karatsu, Kariya, Kobe, Nagasaki, Nishi, Setagaya City
2025-10-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Nagoya, Toyoake, Hirosaki, Tōon, Kurume, Ōta, Himeji, Kobe
2025-10-08
Recruiting
Kazuya Hosokawa
Phase 4
36
Fukuoka, Kobe, Kyoto, Nagoya, Okayama, Sendai, Tokyo
2025-10-07
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Nagoya, Uwajima-shi, Fukuoka, Kitakyushu, Kurume-shi, Sapporo, Himeji, Kobe
2025-10-02
Recruiting
Pfizer
Phase 3
1,000
Chiba, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka, Suita
2025-09-28
Recruiting
Sanofi
Phase 3
124
Kitakyushu, Hiroshima, Sapporo, Kobe, Kahoku, Uchinada, Kanazawa, Nagaoka, Hirakata
2025-09-26
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Akita, Asahikawa, Fukuoka, Hidaka, Hiroshima, Kobe, Matsuyama, Nagoya
2025-09-08
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama
2025-09-02
Recruiting
AstraZeneca
Phase 2
278
Bunkyō City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku
2025-08-07
Recruiting
Sanofi
Phase 3
723
Nagoya, Sapporo, Kobe, Yokohama, Azumino, Shimajiri, Iruma, Koshigaya
2025-08-06
Recruiting
AbbVie
Phase 3
120
Ōbu, Kashiwa-shi, Kurume-shi, Maebashi, Kobe, Kumamoto, Saga, Saitama-shi
2025-07-28
Recruiting
Sanofi
Phase 2
10
Sapporo, Kobe, Yokohama, Iruma, Chūō, Fukuoka, Kyoto, Nagasaki
2025-07-25
Recruiting
Pfizer
Phase 3
714
Tōon, Kurume, Otashi, Asahikawa, Kobe, Yokohama, Tsu, Sendai
2025-07-23
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bunkyō City, Fukuoka, Kagawa, Kashihara, Kobe, Kumamoto, Kurume, Matsumoto-shi
2025-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Nagoya, Sapporo, Kobe, Kamakura, Yokohama, Kumamoto, Chuo Ku, Chiba
2025-07-01
Active, closed
Bayer
Phase 3
36
Kurume, Himeji, Kobe, Tsukuba, Morioka, Sagamihara, Yokohama, Nankoku
2025-06-30
Active, closed
Amgen
Phase 3
279
Nagoya, Fukuoka, Onga-gun, Hashima-gun, Sapporo, Amagasaki-shi, Kobe, Naka
2025-06-13
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bunkyō City, Fukuoka, Fukushima, Gifu, Kanazawa, Kobe, Kumamoto, Maebashi
2025-06-04
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Chiba, Kashiwa, Matsuyama, Fukuoka, Maebashi, Sapporo, Akashi-shi, Kobe
2025-05-22
Recruiting
Pfizer
Phase 2
252
Aki-gun Fuchu-cho, Kobe, Kawachi-Nagano, Sakai, Fujieda, Hamamatsu, Chuo-ku, Hachiōji
2025-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Nagoya, Sakura, Tōon, Kitakyushu, Kurume, Sapporo, Kobe, Kahoku-gun
2025-05-13
Recruiting
Joseph Broderick, MD
Phase 3
350
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Niigata, Osaka
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Bunkyō City, Chiba, Fukuoka, Hiroshima, Iizuka-shi, Kashiwa, Kita-gun, Kobe
2025-05-06
Recruiting
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
NCT06917690Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Chiesi Farmaceutici S.p.A.
Phase 3
6
Fukuoka, Kobe, Niigata, Ōta-ku, Sapporo
2025-04-18
Recruiting
AstraZeneca
Phase 3
830
Akashi, Bunkyō City, Fukuoka, Hamamatsu, Iwakuni-shi, Izumi-shi, Kashihara-shi, Kobe
2025-04-10
Recruiting
Gilead Sciences
Phase 3
695
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe
2025-04-04
Recruiting
Daiichi Sankyo
Phase 3
510
Chūōku, Hiroshima, Kashiwa, Kita-gun, Kobe, Kōtoku, Matsuyama, Nagoya
2025-03-27
Recruiting
AstraZeneca
Phase 3
600
Akashi-shi, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa, Kashiwa-shi, Kobe, Kōtoku
2025-03-27
Recruiting
AstraZeneca
Phase 2
540
Fukuoka, Ginowan-shi, Hiroshima, Ishinomaki, Kawaguchi-shi, Kiyose-shi, Kobe, Meguro-ku
2025-03-26
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Chiba, Sapporo, Kobe, Sendai, Suita, Bunkyo Ku, Shinjuku-ku, Fukuoka
2025-03-13
Recruiting
Pfizer
Phase 3
723
Kobe, Kyoto-shi Shimogyo-ku, Sendai, Shibuya-ku, Kai, Kagoshima
2025-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Kashiwa, Sapporo, Kobe, Yokohama, Chiba, Fukuoka, Fukushima, Ishikawa
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Matsuyama, Kurume, Sapporo, Kobe, Kanazawa, Yokohama, Sendai, Kashihara
2025-02-25
Recruiting
AbbVie
Phase 3
420
Kobe, Kochi, Osaka, Shibuya-ku, Shinjuku-ku, Tendo-shi, Kai, Kagoshima
2025-02-13
Active, closed
AbbVie
Phase 3
468
Kobe, Kawasaki-shi, Kochi, Sendai, Ōita, Osaka, Setagaya-ku, Shibuya-ku
2025-02-10
Recruiting
BioNTech SE
Phase 3
621
Ageo, Bunkyō City, Chūōku, Fukuoka, Hidaka, Himeji, Iwakuni, Kobe
2025-02-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Nagoya, Kashiwa, Matsuyama, Kobe, Kanazawa, Isehara, Sendai, Sakai
2025-01-27
Recruiting
AbbVie
Phase 2
150
Nagoya, Kashiwa-shi, Sapporo, Kobe, Sagamihara-shi, Sendai, Miyazaki, Kurashiki-shi
2025-01-20
Recruiting
Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
NCT06776549Out-of-hospital Cardiac Arrest (OHCA), ECMO Treatment, Temperature, Post Cardiac Arrest Syndrome
Kagawa University
Not applicable
468
Kurume, Asahikawa, Sapporo, Kakogawa, Kobe, Toyooka, Hitachi-shi, Kita-gun
2025-01-06
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
23
Nagoya, Sapporo, Kobe, Osaka, Chuo-ku, Chiba, Fukuoka, Fukushima
2024-11-25
Active, closed
Genmab
Phase 3
191
Matsuyama, Kitakyushu-shi, Hiroshima, Kobe, Kumamoto, Osakasayama-shi, Bunkyō City, Chūōku
2024-11-25
By invitation
CoreTissue BioEngineering Inc.
Not applicable
64
Hirosaki, Hiroshima, Sapporo, Kobe, Bunkyo-ku, Shinjuku-ku
2024-11-25
Active, closed
Pfizer
Phase 3
200
Kobe, Nishinomiya, Osaka, Shibuya-ku, Kai, Kagoshima
2024-11-15
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Narashino, Sapporo, Kobe, Yokohama, Okayama, Suita, Chiyoda City
2024-10-29
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Fuchū, Kanazawa, Kobe, Kumamoto, Matsumoto, Saga, Yokohama
2024-10-29
Active, closed
Eli Lilly and Company
Phase 3
1,400
Bunkyō City, Chūōku, Fujisawa, Fukuoka, Hachiōji, Himeji, Imabari, Kobe
2024-10-24
Recruiting
Pfizer
Phase 3
900
Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka
2024-10-22
Active, closed
Pfizer
Phase 3
600
Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka
2024-10-21
Active, closed
Incyte Corporation
Phase 3
346
Bunkyō City, Inashiki-gun, Kamimashiki-gun, Kawasaki-shi, Kitakyushu, Kobe, Kumamoto, Minamikoshigaya
2024-10-10
Active, closed
AstraZeneca
Phase 3
768
Bunkyō City, Fukuoka, Hiroshima, Iruma-Gun, Iwakuni-shi, Kobe, Kōtoku, Kumamoto
2024-10-04
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Nagakute, Nagoya, Narita, Matsuyama, Fukuoka, Hiroshima, Kobe, Hitachi
2024-10-01
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Chiba, Sapporo, Kobe, Yokohama, Sendai, Suita, Izumo, Bunkyo Ku
2024-09-04
Recruiting
Bayer
Phase 3
444
Nagoya, Kashiwa, Sapporo, Himeji, Kobe, Sagamihara, Sendai, Hirakata
2024-08-28
Recruiting
AstraZeneca
Phase 3
1,018
Bunkyō City, Chiba, Chuo-shi, Fukuoka, Hirakata-shi, Kobe, Kōtoku, Kumamoto
2024-08-07
Active, closed
Belite Bio, Inc
Phase 2/3
60
Kobe, Kyoto, Tokyo
2024-07-31
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Chofu-shi, Chūōku, Hirakata-shi, Kobe, Musashimurayama, Narashino-shi, Shinjuku Ku, Shinjuku-ku
2024-07-22
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Asahikawa, Bunkyō, Chikushino-shi, Kashiwa-shi, Kobe, Kofu, Nagasaki, Nara
2024-07-18
Recruiting
Revolade Tablets Specified Drug-use Survey
NCT06287268Aplastic Anemia
Novartis Pharmaceuticals
Observational
10
Nagoya, Toyoake, Chiba, Amagasaki, Kobe, Matsumoto, Shimajiri-Gun, Izumi
2024-07-17
Active, closed
Vor Biopharma
Phase 3
191
Nagoya, Sapporo, Kobe, Kawasaki, Yokohama, Sendai, Kashiwazaki-Shi, Ginowan-Shi
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Toyoake, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai, Hirakata
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Nagoya, Toyoake, Hirosaki, Kashiwa, Tōon, Ōta, Kobe, Takarazuka
2024-06-10
Active, closed
Sanofi
Phase 3
1,541
Chitose, Obihiro, Sapporo, Kobe, Sagamihara, Yokohama, Miyagi-gun, Sendai
2024-05-08
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Amagasaki Shi, Kawasaki Shi, Kobe, Kumamoto, Osaka, Ōta-ku, Saitama, Wakayama
2024-04-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Kashiwa, Matsuyama, Kitakyushu, Kobe, Kawasaki, Yokohama, Hirakata, Sakai
2024-04-03
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Bunkyō City, Chiba, Fukuoka, Kamakura, Kasugai-shi, Kitakyushu-shi, Kobe, Matsumoto-shi
2024-03-29
Recruiting
AstraZeneca
Phase 3
100
Bunkyō City, Chiba, Fuchu-shi, Kawasaki-shi, Kobe, Nagasaki, Obu-shi, Shinjuku-ku
2024-03-14
Recruiting
Eli Lilly and Company
Phase 3
90
Bunkyō City, Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-ku
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya Ku, Tokyo
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Kashiwa, Sapporo, Kobe, Yokohama, Chuo Ku, Fukuoka, Fukushima, Ishikawa
2024-03-12
Active, closed
Samsung Bioepis Co., Ltd.
Phase 3
555
Himeji, Iwakuni, Izumi, Kawachi-Nagano, Kobe, Kochi, Sagamihara, Tachikawa
2024-03-12
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Nagoya, Kashiwa-shi, Matsuyama, Kurume, Ota-Shi, Kobe, Kanazawa, Yokohama
2024-02-21
Recruiting
AstraZeneca
Phase 3
5,250
Chūōku, Fujieda-shi, Fukuoka, Kitakyushu, Kobe, Kure-shi, Kyoto, Minoh
2024-02-21
Recruiting
Pfizer
Phase 3
492
Toyohashi, Matsuyama, Maebashi, Shibukawa, Kobe, Shiwa-gun Yahaba-cho, Bunkyo-ku, Koto
2024-02-08
Active, closed
Genmab
Phase 3
1,095
Toyoake, Matsuyama, Yoshida-gun, Fukuoka, Fukuyama, Sapporo, Kobe, Hitachi-shi
2024-02-05
Active, closed
Janssen Research & Development, LLC
Phase 3
112
Fuchū, Kanazawa, Kobe, Kumamoto, Matsumoto, Saga, Setagaya Ku, Shinjuku
2024-01-19
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Kobe, Yokohama, Hirakata
2024-01-18
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
185
Nagakute, Nagoya, Sakura, Kurume, Kōriyama, Sapporo, Kobe, Mito
2024-01-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Sakura, Tōon, Kitakyushu, Kurume, Asahikawa, Sapporo, Kobe, Mukai-awagasaki
2023-12-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Toyoake, Kashiwa, Tōon, Sapporo, Kobe, Kanazawa, Tsu, Sendai
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Sakura, Eiheiji-cho,Yoshida-gun, Kitakyushu, Sapporo, Kobe, Mukai-awagasaki, Kita, Yokohama
2023-12-18
Recruiting
AstraZeneca
Phase 3
1,145
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe
2023-12-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Maebashi, Sapporo, Kobe, Sendai, Sakai, Izumo, Koto
2023-12-13
Active, closed
Incyte Corporation
Phase 3
467
Hamamatsu, Kawasaki, Kobe, Kyoto, Minamikoshigaya, Nagasaki, Nagoya, Nankoku
2023-11-29
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
189
Nagoya, Kashiwa, Matsuyama, Hiroshima, Kobe, Yokohama, Kumamoto, Sendai
2023-11-01
Recruiting
AbbVie
Phase 3
90
Kobe, Kawasaki-shi, Niigata, Takatsuki-shi, Bunkyo-ku
2023-10-02
Recruiting
Kyoto University Hospital
Phase 2
30
Kobe, Tsukuba, Kyoto, Osaka
2023-10-01
By invitation
Sarepta Therapeutics, Inc.
Phase 3
400
Kobe, Kodaira, Tokyo
2023-09-27
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Fukuoka, Ota-Shi, Kobe, Tsukuba, Kita-gun, Yokohama, Tokushima, Wakayama
2023-09-22
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Chiba, Fukuoka, Koriyama-shi, Naka-gun, Hiroshima, Sapporo, Himeji-Shi, Kobe
2023-09-14
Recruiting
Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula
NCT07862088Acute Pancreatitis, Pancreatic Fluid Collection, Postoperative Pancreatic Fistula
Tokyo University
Observational
5,000
Ōtsu, Bunkyō-Ku, Tokyo, Gifu, Hyōgo, Kawagoe, Kobe, Ōsaka-sayama
2023-09-14
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
141
Sapporo, Kobe, Yokohama, Sendai, Matsumoto, Mitaka, Gifu
2023-08-22
Recruiting
MiMedx Group, Inc.
Not applicable
75
Kobe, Iruma-gun, Bunkyō-Ku, Mitaka-shi, Shinjuku-Ku
2023-08-04
Active, closed
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498Percutaneous Coronary Intervention
CathWorks Ltd.
Not applicable
1,924
Fukuyama, Gifu, Ichinomiya, Kobe, Matsudo, Osaka, Tokyo
2023-06-21
By invitation
AbbVie
Phase 3
650
Kobe, Nishinomiya-shi, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-06-05
Active, closed
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
DrugDupilumab
Regeneron Pharmaceuticals
Phase 2
22
Iizuka, Ōgaki, Kure, Himeji, Kobe, Yokohama, Kurashiki, Minato-ku
2023-05-03
Recruiting
AbbVie
Phase 3
450
Kobe, Nishinomiya, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-05-01
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Fuji-shi, Kanazawa, Kashihara-shi, Kisarazu-shi, Kobe, Kumamoto, Nagano, Nagasaki
2023-03-23
Active, closed
Genmab
Phase 3
900
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe, Tsukuba
2023-02-08
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Narita, Matsuyama, Gifu, Kobe, Isehara, Suita, Itabashi-ku, Shinjuku Ku
2022-12-30
Recruiting
Pfizer
Phase 3
100
Kobe, Azumino, Kashihara, Saga, Saitama-shi
2022-12-09
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Nagakute-shi, Nagoya, Sakura-shi, Sapporo, Kobe, Yokohama, Shimotsuke-shi, Chiyoda-ku
2022-11-21
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kobe, Kita-gun, Kawasaki-shi
2022-10-24
Recruiting
PedAL BCU, LLC
Phase 3
130
Nagoya, Kobe, Saitama-Shi, Setagaya-Ku, Osaka
2022-10-01
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Asahikawa, Bunkyō City, Chiba, Hamamatsu, Isehara, Kobe, Kodaira-shi, Koshigaya
2022-09-23
Active, closed
Eli Lilly and Company
Phase 2
46
Kobe, Chuo-ku, Fukuoka
2022-09-20
Active, closed
Genmab
Phase 3
549
Nagoya, Toyoake, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe
2022-09-20
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Kobe
2022-08-30
Active, closed
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
NCT05814159Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
DrugAnakinra
Swedish Orphan Biovitrum
Phase 3
15
Fukushima, Kobe, Yokohama, Matsumoto, Bunkyō-Ku, Shinjuku-Ku, Gifu
2022-08-24
Active, closed
Eli Lilly and Company
Phase 3
925
Nagoya, Kashiwa, Kisarazu, Sakura, Sapporo, Kobe, Kanazawa, Kita
2022-04-14
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Nagoya, Toyoake-shi, Chiba, Urayasu-shi, Kobe, Tsukuba, Kawasaki-shi, Kashihara
2022-04-05
Active, closed
AstraZeneca
Phase 3
1,035
Chiba, Hirakata-shi, Hirosaki-shi, Kanazawa, Kashihara-shi, Kita-gun, Kobe, Kumamoto
2022-03-25
Active, closed
Pfizer
Phase 3
854
Nagoya, Maebashi, Kobe, Yahaba-cho, Kyoto, Sendai, Hamamatsu, Sunto-gun
2022-03-25
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Nagoya, Toyoake, Urayasu, Kurume, Amagasaki, Kobe, Tsukuba, Kanazawa
2022-03-15
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Nagoya, Fukushima, Kobe, Nishinomiya-shi, Kagoshima, Kyoto, Miyazaki, Ōtsu
2022-01-13
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
Kobe, Nankoku, Ginowan-Shi, Shimajiri, Kawagoe, Bunkyo, Shinjuku, tabashi City
2021-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Nagoya, Chiba, Ichihara, Fukuoka, Sapporo, Kobe, Nishinomiya, Isehara
2021-12-13
Active, closed
Joseph Broderick, MD
Phase 3
860
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Morioka, Niigata
2021-12-03
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gunma, Hyōgo, Kanagawa, Kobe, Kurume, Nagoya, Niigata, Osaka
2021-11-17
Recruiting
AbbVie
Phase 1
694
Nagoya, Kashiwa-shi, Kobe, Hirakata-shi, Sunto-gun, Chuo-ku, Wakayama
2021-11-01
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Nagoya, Toyoake, Sapporo, Kobe, Kurashiki, Sakai, Suita, Shimotsuke
2021-10-06
Active, closed
Eli Lilly and Company
Phase 3
874
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Sapporo, Akashi, Kobe
2021-10-04
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
65
Toyoake, Chiba, Kashiwa, Sapporo, Kobe, Kawasaki, Yokohama, Kurashiki
2021-09-23
Active, closed
Tanabe Pharma America, Inc.
Phase 3
286
Kobe, Kanazawa, Takatsuki, Minato-ku, Sugitani, Shizuoka
2021-08-10
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Hokkaido, Kobe, Kumamoto, Kyoto, Nagasaki, Osaka, Saitama, Toyoake
2021-07-06
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Nagoya, Sapporo, Kobe, Yokohama, Kumamoto, Suita, Kitaadachi-gun, Bunkyo Ku
2021-06-09
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Bunkyō, Bunkyō City, Kashiwa, Kobe, Tokyo, Yokohama
2021-05-26
Active, closed
Daiichi Sankyo
Phase 3
490
Nagoya, Chūōku, Gifu, Kashiwa, Kobe, Kochi, Kōtoku, Matsuyama
2021-05-21
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Fukuoka, Fukushima, Kanazawa, Kashiwa, Kobe, Maebashi, Nagoya, Sapporo
2021-05-19
Active, closed
Incyte Corporation
Phase 3
654
Fukuoka, Fukuyama-shi, Gifu, Kagoshima, Kashiwa-shi, Kitakyushu-shi, Kobe, Nagoya
2021-04-15
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Nagoya, Sapporo, Kobe, Sendai, Osaka Sayama-shi, Kawagoe, Koto, Hiroshima
2021-04-08
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Nagoya, Ogaki-shi, Sapporo, Kobe, Isehara, Nankoku, Sendai, Osaka Sayama-shi
2021-03-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Toyoake, Kashiwa, Sakura, Sapporo, Kobe, Yokohama, Kashihara, Sakai
2021-02-25
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Chiba, Fukuoka, Gifu, Hokkaido, Kobe, Koshigaya, Kumamoto, Kurashiki
2021-02-01
Active, closed
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
NCT05931445Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer
Comprehensive Support Project for Oncology Research
Not applicable
500
Kobe
2021-01-26
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
40
Kashiwa-shi, Kobe, Yokohama, Ina, Osaka, Takatsuki-shi, Hidaka-shi, Koto-Ku
2021-01-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Nagoya, Kobe, Takarazuka, Yokohama, Hirakata, Takatsuki, Nakatogari, Fukuoka
2020-12-08
Active, closed
Eli Lilly and Company
Phase 3
312
Kagoshima, Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Shinjuku-ku, Tokyo
2020-11-25
Active, closed
Bayer
Phase 3
402
Nagoya, Asahi, Sakura, Maebashi, Sapporo, Kobe, Higashiibaraki, Sagamihara
2020-10-20
Active, closed
Exelixis
Phase 3
575
Toyota-shi, Akita, Hirosaki, Kashiwa-shi, Sakura-shi, Sapporo, Kobe, Kita-gun
2020-10-19
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Bunkyō City, Hidaka, Himeji, Hirakata, Kanazawa, Kashiwa, Kishiwada, Kobe
2020-10-13
Active, closed
Acerta Pharma BV
Phase 3
611
Chiba, Chūōku, Fukuoka, Itabashi-ku, Kahoku-gun, Kashiwa, Kobe, Kōtoku
2020-10-08
Active, closed
AstraZeneca
Phase 3
370
Chūōku, Fukuoka, Hiroshima, Isehara-shi, Kashiwa, Kobe, Kōtoku, Okayama
2020-10-02
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Nagoya, Toyohashi, Kashiwa, Matsuyama, Ōta, Sapporo, Kobe, Yokohama
2020-09-16
Active, closed
AbbVie
Phase 3
531
Nagoya, Yoshida-gun, Fukuoka, Fukushima, Fukuyama, Sapporo, Kobe, Higashiibaraki-gun
2020-09-10
Active, closed
Incyte Corporation
Phase 2
112
Bunkyō City, Chūō, Hirakata, Isehara, Kobe, Kyoto, Matsumoto-shi, Miyagi
2020-08-03
Active, closed
Eisai Inc.
Phase 3
1,400
Obu-shi, Fukuoka, Kobe, Kamakura-shi, Kyoto, Sendai, Osaka, Suita-shi
2020-07-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Kurume, Kobe, Yokohama, Hirakata, Takatsuki, Fukuoka, Niigata, Osaka
2020-07-06
Active, closed
Actelion
Phase 3
935
Bunkyō City, Fukuoka, Hiroshima, Kagoshima, Kanagawa, Kanazawa, Kobe, Kurume
2020-06-30
Active, closed
Eli Lilly and Company
Phase 3
1,736
Nagoya, Ōbu, Inage, Akashi, Himeji, Kobe, Inashiki, Toride
2020-06-19
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Nagoya, Kashiwa, Sapporo, Kobe, Yokohama, Suita, Koto, Fukuoka
2020-02-11
Recruiting
Eli Lilly and Company
Phase 2
105
Chūōku, Fukuoka, Kobe
2020-01-22
Recruiting
McMaster University
Not applicable
352
Kobe
2020-01-01
Recruiting
Study of Out of Specification for Tisagenlecleucel
NCT04094311B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
DrugTisagenlecleucel
Novartis Pharmaceuticals
Phase 3
200
Nagoya, Tōon, Gifu, Sapporo, Kobe, Nishinomiya, Tsukuba, Kita-gun
2019-11-21
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Kobe, Isehara-Shi, Kyoto
2019-11-13
Active, closed
Bristol-Myers Squibb
Phase 3
461
Nagoya, Kashiwa-shi, Kitakyushu-shi, Hiroshima, Kobe, Kanazawa, Yokohama, Sendai
2019-11-05
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Kobe, Higashi Ibaraki-gun, Okayama, Chuo-ku
2019-09-06
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Chūōku, Hirakata, Kashiwa, Kobe, Nagoya, Okayama, Shizuoka
2019-09-04
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hirosaki-shi, Chiba, Kashiwa-Shi, Matsuyama, Fukuoka, Kobe, Tsukuba, Kanazawa
2019-08-09
Active, closed
National Cancer Center Hospital East
Phase 2
51
Nagoya, Kashiwa, Hokkaido, Akashi, Kobe, Yokohama, Sendai, Osaka
2019-07-02
Active, closed
AbbVie
Phase 1
124
Obu-shi, Kobe, Kagoshima, Kawasaki-shi, Sendai, Niigata, Bunkyo-ku
2019-06-24
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Akita, Chiba, Chūōku, Hakodate, Hirosaki, Kanazawa, Kobe, Koshigaya
2019-06-11
Recruiting
AstraZeneca
Phase 3
140
Bunkyō City, Fuchu-shi, Fukuoka, Kawasaki-shi, Kobe, Matsumoto-shi, Nakagami-gun, Saitama-Shi
2019-04-02
Active, closed
Eisai Inc.
Phase 3
1,906
Obu-shi, Chiba, Eiheiji-cho, Yoshida-gun, Fujioka-shi, Ōtake, Sapporo, Himeji-shi, Kobe
2019-03-27
Recruiting
Jerry Zimmerman
Phase 3
500
Kobe, Nagoya
2019-03-11
Active, closed
AstraZeneca
Phase 3
724
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Kobe, Niigata
2019-03-06
Active, closed
AstraZeneca
Phase 3
1,407
Fukuoka, Kashiwa-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya
2019-01-04
Active, closed
Eli Lilly and Company
Phase 2/3
393
Nagoya, Hirosaki, Sakura, Sapporo, Kobe, Kanazawa, Yokohama, Ina-machi
2018-11-26
Active, closed
AbbVie
Phase 3
265
Nagoya, Kashiwa-shi, Fukuoka, Ogaki-shi, Maebashi, Hiroshima, Kobe, Higashi Ibaraki-gun
2018-10-22
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Nagoya, Kashiwa, Matsuyama, Sapporo, Kobe, Suita, Hidaka, Kitaadachi-gun
2018-06-21
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Chiba, Hirosaki, Kashiwa, Kita Gun, Kobe, Koshigaya, Matsuyama, Miyazaki
2018-03-23
Active, closed
Eli Lilly and Company
Phase 3
533
Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Sendai, Shinjuku-ku, Tokyo
2018-03-14
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Matsuyama, Fukui, Himeji, Kobe
2017-06-26
Active, closed
Regeneron Pharmaceuticals
Phase 1
146
Nagoya, Kurume, Ōta, Kobe, Kanazawa, Sagamihara, Yokohama, Sasebo
2017-06-21
Active, closed
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03155191Lymphoblastic Leukemia, Acute Adult
Takara Bio Inc.
Phase 1/2
21
Akita, Yoshida, Higashiku, Sapporo, Kobe, Tsu, Sendai, Okayama
2017-06-01
Recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor
DrugsBleomycin·Cis-platinum·CDDP·Paraplatin
Children's Oncology Group
Phase 3
1,780
Sendai, Chiba-sgi, Niigata, Higashiku, Sapporo, Kobe, Tsukuba, Yokohama
2017-05-25
Active, closed
Acerta Pharma BV
Phase 3
635
Fukuoka, Kobe, Kyoto, Matsuyama, Nagoya, Osaka, Sapporo, Sendai
2017-04-05
Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
NCT02708134Cardiac Arrest, Cardiopulmonary Arrest
Children's Hospital of Philadelphia
Observational
7,000
Aichi, Kobe, Tokyo
2016-05-02
Active, closed
AstraZeneca
Phase 3
682
Bunkyō City, Fukuoka, Hirakata-shi, Hiroshima, Kanazawa, Kashiwa, Kitakyushu-shi, Kobe
2015-10-21
Recruiting
C-Brace Prospective Registry
NCT04640584Pareses, Lower Extremity
Otto Bock Healthcare Products GmbH
Observational
250
Kobe
2015-04
Recruiting
Boston Scientific Corporation
Observational
4,800
Kobe, Nishinomiya-shi, Okayama, Sakaishi
2012-11-19
Recruiting
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Children's Hospital of Philadelphia
Observational
150,000
Setagaya-Ku, Hiroshima, Kobe, Ōbu, Saitama, Shimotsuke, Tokyo
2010-03
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Hirakata, Hokkaido, Itabashi Ku, Kobe, Kurume, Matsumoto, Ōita, Takamatsu
2007-06-21
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Kobe, Nankoku, Chiba, Niigata, Osaka, Tokyo
2001-07-31
Rows per page Showing 1–236 of 236
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kobe

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 236 of those studies with a site in Kobe.

How many clinical trials are recruiting in Kobe?

134 of the 236 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 97 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kobe), 236 studies
PhaseStudiesRecruitingShare
Phase 31618868.2%
Phase 2291712.3%
Phase 11255.1%
Observational1084.2%
Not applicable953.8%
Phase 2/3853.4%
Phase 1/2542.1%
Phase 4220.8%

Most active sponsors

Lead sponsors with the most studies (Kobe)
Lead sponsorStudiesRecruiting
AstraZeneca2317
Eli Lilly and Company1911
Janssen Research & Development, LLC1811
Merck Sharp & Dohme LLC1611
Novartis Pharmaceuticals169
AbbVie158
Pfizer128
Bristol-Myers Squibb86
Incyte Corporation51
Sanofi54
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.